Arogga LogoArogga Home
Crizocent 250 - Image 1
Out Of Stock

ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন

Register
1980 people viewed this
info-icon
info-icon

Crizocent 250

Capsule-(250mg)
brand logo
Incepta Pharmaceuticals Ltd.

Generic: Crizotinib

60 Capsules (1 Box)
৳ 81810
৳ 90000
9% OFF
Alternative Brands For Crizocent 250

Medicine Overview of Crizocent 250mg Capsule

Switch language Iconবাংলা

Introduction

Crizocent 250 is used in the treatment of non-small cell lung cancer that is locally advanced or has spread to other areas of the body. Crizocent 250 should be taken with food or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. Nausea, vomiting, edema (swelling), and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits. Your doctor may perform some blood tests during the treatment to check for liver function. Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses of Crizocent 250

  • Non-small cell lung cancer

Side effects of Crizocent 250

Common
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Visual impairment
  • Dizziness
  • Taste change
  • Fatigue
  • Decreased appetite
  • Rash
  • Decreased white blood cell count (neutrophils)

How to use Crizocent 250

Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Crizocent 250 may be taken with or without food, but it is better to take it at a fixed time.

How Crizocent 250 works

Crizocent 250 is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

What if you forget to take Crizocent 250?

If you miss a dose of Crizocent 250, skip it and continue with your normal schedule. Do not double the dose.

Quick Tips

  • Crizocent 250 helps in the treatment of non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
  • Take it at the same time each day, with or without food.
  • Diarrhea, nausea and vomiting may occur with Crizocent 250. Stay hydrated and inform your doctor if it persists.
  • It may cause dizziness or blurring of vision. Don't drive or do anything requiring concentration until you know how it affects you.
  • Inform your doctor if you experience severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits.
  • Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.
  • Do not take Crizocent 250 if you are pregnant or breastfeeding. Use reliable methods of contraception to prevent pregnancy while taking this medicine.

Brief Description

Indication

Non-Small Cell Lung Cancer, Indicated for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive Indicated for metastatic NSCLC tumors that are ROS1-positive

Administration

Take with or without food; a high-fat meal reduces AUCinf and Cmax by ~14% Capsules should be swallowed whole

Adult Dose

Oral Adult Non-Small Cell Lung Cancer Indicated for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Also indicated for metastatic NSCLC tumors that are ROS1-positive. Select patients for treatment of metastatic NSCLC based on presence of ALK or ROS1 positivity in tumor specimens. Capsule 250 mg PO q12hr Continue treatment as long as patient is deriving clinical benefit from therapy Dose Modifications Dosing interruption and/or dose reduction to 200 mg PO q12hr may be required based on safety and tolerability; decrease to 250 mg PO qDay if further reduction is needed Hepatic impairment: Caution advised

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment Mild-to-moderate (CrCl 30-90 mL/min): No starting dose adjustment is needed; steady-state trough concentrations in these 2 groups were similar to those with normal renal function (ie, CrCl >90 mL/min) Severe (CrCl <30 mL/min) or end-stage renal disease: Caution advised

Contraindication

Hypersensitivity

Mode of Action

Inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON) The gene’s expression and signaling that contribute to increased cell proliferation and survival of the tumors become activated following the expression of ALK oncogenic fusion proteins Inhibits the signaling that promotes the expression of these oncogenic fusion proteins, thereby inhibiting tumor cell proliferation

Precaution

Severe, including fatal, treatment-related pneumonitis reported; monitor for pulmonary symptoms indicative of pneumonitis and permanently discontinue if diagnosed Hepatoxicity reported; elevations in ALT and total bilirubin reported; monitor q2wk for 2 months, then monthly and as clinically indicated with more frequent testing with Grade 2-4 elevations; temporarily suspend, reduce dose, or permanently discontinue dose as indicated (see Dose Modifications) Symptomatic bradycardia reported, including syncope; avoid coadministration with other drugs known to cause bradycardia; monitor heart rate and blood pressure regularly; temporarily suspend, reduce dose, or permanently discontinue (see Dosage Modifications) Caution when driving or operating machinery because of vision disorder, dizziness, or fatigue associated with treatment Can cause fetal harm when administered to pregnant women (see Pregnancy) Interstitial Lung Disease (ILD)/Pneumonitis reported; permanently discontinue in patients with ILD/pneumonitis Visual field defect with vision loss reported; optic atrophy and optic nerve disorder have been reported as potential causes of vision loss; discontinue with new onset of severe visual loss Lactation There is no information regarding the presence of crizotinib in human milk, the effects on the breastfed infant, or the effects on milk production Because of the potential for adverse reactions in breastfed infants, do not breastfeed during treatment and for 45 days after the final dose

Side Effect

>10% ALT elevation (76%),AST elevation (61%),Vision disorder (60%),Diarrhea (60%),Nausea (55%),Lymphopenia (51%),Neutropenia (49%),Vomiting (47%),Constipation (42%),Edema (31%),Hypophosphatemia (28%),Decreased appetite (27%),Fatigue (27%),Dysgeusia (26%),Upper respiratory infection (26%),Dizziness (22%),Neuropathy (19%),Dysesthesia (19%),Gait disturbance (19%),Hypoesthesia (19%),Muscular weakness (19%),Neuralgia (19%),Peripheral neuropathy (19%),Paresthesia (19%),Peripheral sensory neuropathy (19%),Polyneuropathy (19%),Burning sensation in skin (19%),Hypokalemia (18%) 1-10% Weight decreased (10%),Rash (9%),Dyspepsia (8%),Pulmonary embolism (6%),QT prolongation (5%),Bradycardia (5%),Pneumonia (4.1%),Pneumonitits (4%),Renal cyst (4%),ARDS (4%),Pulmonary embolism (3.5%),Syncope (3%),Dyspnea (2.3%),Hepatic failure (1%),Esophagitis (2%) <1% Vision loss, grade 4 (0.2%),Hypogonadism; decreased blood testosterone (1%)

Pregnancy Category Note

Pregnancy Based on its mechanism of action, can cause fetal harm when administered to a pregnant woman Contraception Advise females of reproductive potential to use effective contraception during treatment and for at least 45 days following the final dose Advise males taking crizotinib with female partners of reproductive potential to use condoms during treatment and for at least 90 days after the final dose

Buy Crizocent 250 from Arogga

In Bangladesh, you can get the original Crizocent 250. Select your favorite one from a large collection of medicine products. Order from App to get more offers and better experience.

What is the price of Crizocent 250 in Bangladesh?

The latest price of Crizocent 250 in Bangladesh is 81810৳. You can buy Crizocent 250 at the best price from Arogga. Order online through our website or mobile app and get fast home delivery anywhere in Bangladesh. Cash on Delivery (COD) is available all over Bangladesh.

Frequently Questions & Answers

Is the product authentic?

Yes. Arogga sources all medicines and health products directly from trusted suppliers, distributors, or manufacturers. Every product is verified before delivery.

Does Arogga deliver all over Bangladesh?

Yes, Arogga delivers nationwide. You can order from anywhere in Bangladesh.

Is Cash on Delivery(COD) available?

Yes, Cash on Delivery is available across Bangladesh for most products.

How long does delivery take?

Delivery usually takes 24–48 hours inside Dhaka and 3–5 days outside Dhaka, depending on location and courier load.

Can I return or replace the product?

If the product is damaged, incorrect, or expired, you can request a replacement or refund according to Arogga’s return policy.

Safety Advices

Rocket Icon
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Crizocent 250. Please consult your doctor.
Rocket Icon
CONSULT YOUR DOCTOR
Crizocent 250 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Rocket Icon
CONSULT YOUR DOCTOR
Crizocent 250 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Rocket Icon
UNSAFE
Crizocent 250 may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Rocket Icon
CAUTION
Crizocent 250 should be used with caution in patients with severe kidney disease. Dose adjustment of Crizocent 250 may be needed. Please consult your doctor.
Rocket Icon
CAUTION
Crizocent 250 should be used with caution in patients with liver disease. Dose adjustment of Crizocent 250 may be needed. Please consult your doctor. Use of Crizocent 250 may not be advised in patients with the severe liver disease.

You May Also Like

see all

More from Incepta Pharmaceuticals Ltd.

see all
Disclaimer

The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.